Pulmonary function testing

Cystic Fibrosis Therapeutics Market Report 2023: Advancements in R&D Progress Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Medical Devices, Health, Stem Cells, Physical Therapy, Managed Care, Pharmaceutical, Distribution (marketing), Liver, Administration, Route of administration, Mucus, Chest infection, Upper respiratory tract infection, CF, Pulmonary function testing, IRT, Agent handling, Route, Medication, Patient, Inflammation, Chest pain, Project delivery method, Research, Gland, Pharmacy, Therapy, CFTR, Sodium, Inhalation, Gastrointestinal tract, Pancreas, Disease, US, Genetic, Medical device, Feces, Blood pressure, Dietary supplement, Pharmaceutical industry, Others, Growth, Perspiration, Cystic fibrosis, Hospital

Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.

Key Points: 
  • Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis.
  • The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in R&D of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance.
  • On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic.
  • In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.

Growth Through Partnership- KoKo, LLC & RBC Medical Innovations

Retrieved on: 
Thursday, July 22, 2021
Respiratory therapy, Pulmonary function testing, Lung, Respiratory system

The partnership between KoKo, LLC and RBC Medical Innovations significantly contributes to these ongoing efforts by expanding the manufacturing of world-renowned diagnostic pulmonary function testing equipment.

Key Points: 
  • The partnership between KoKo, LLC and RBC Medical Innovations significantly contributes to these ongoing efforts by expanding the manufacturing of world-renowned diagnostic pulmonary function testing equipment.
  • RBC Medical Innovations' experience and success proved to be the perfect match.
  • Based in Longmont, Colorado, KoKo, LLC extends the legacy of medical technologies that have been providing the highest quality pulmonary function testing products since the 1930's.
  • As a software developer and medical device manufacturer, KoKo produces respiratory solutions with high-speed testing, cost-effective lifecycles, and unparalleled accuracy.

Growth Through Partnership- KoKo, LLC & RBC Medical Innovations

Retrieved on: 
Thursday, July 22, 2021
Respiratory therapy, Pulmonary function testing, Lung, Respiratory system

The partnership between KoKo, LLC and RBC Medical Innovations significantly contributes to these ongoing efforts by expanding the manufacturing of world-renowned diagnostic pulmonary function testing equipment.

Key Points: 
  • The partnership between KoKo, LLC and RBC Medical Innovations significantly contributes to these ongoing efforts by expanding the manufacturing of world-renowned diagnostic pulmonary function testing equipment.
  • RBC Medical Innovations' experience and success proved to be the perfect match.
  • Based in Longmont, Colorado, KoKo, LLC extends the legacy of medical technologies that have been providing the highest quality pulmonary function testing products since the 1930's.
  • As a software developer and medical device manufacturer, KoKo produces respiratory solutions with high-speed testing, cost-effective lifecycles, and unparalleled accuracy.

ERT Announces Real-Time Coaching for Pulmonary Function Tests Performed in the Patient's Home

Retrieved on: 
Tuesday, June 8, 2021
Respiratory therapy, Clinical medicine, Health care, Medicine, ERT, Medical tests, Pulmonary function testing, Spirometry

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).

Key Points: 
  • PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).
  • With iSpiro Virtual Visits, ERT delivers on its commitment to provide customer and patient-oriented innovations that facilitate decentralization.
  • "Performing spirometry correctly can be critical to the success of a drug approval," said Achim Schlke, Executive Vice President of ERT Respiratory Solutions.
  • By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.

Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis

Retrieved on: 
Wednesday, March 17, 2021
Clinical medicine, Medical specialties, Medicine, Respiratory therapy, Excipients, Lung disorders, Glycerols, Mannitol, Cystic fibrosis, Pulmonary function testing, Bronchiectasis

Bronchitol is the first and only dry powder inhaled mucoactive agent* providing a compact, portable option for patients.

Key Points: 
  • Bronchitol is the first and only dry powder inhaled mucoactive agent* providing a compact, portable option for patients.
  • Bronchitol was developed by Pharmaxis Ltd., and Chiesi is now its exclusive distributor in the United States and 11 countries in Europe.
  • *The precise mechanism of action of BRONCHITOL in improving pulmonary function in CF patients is unknown.
  • BRONCHITOL (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.

Study Finds MediPines' Breakthrough Non-invasive Gas Exchange Method Highly Precise: Ideal for Covid Response

Retrieved on: 
Monday, February 1, 2021
Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Breath tests, Respiratory therapy, Anesthesia, Respiratory system, Monitoring, Breath gas analysis, Pulmonary function testing

Using the MediPines AGM100 , a respiratory medical device,researchers were able to demonstrate that the new breath-based measurement of gas exchange efficiency has very low variability and is highly correlated with established blood-sampling methods.

Key Points: 
  • Using the MediPines AGM100 , a respiratory medical device,researchers were able to demonstrate that the new breath-based measurement of gas exchange efficiency has very low variability and is highly correlated with established blood-sampling methods.
  • A breath-based gas exchange analysis using the AGM100 is easy to obtain for both practitioner and patient.
  • The gas exchange analysis provided by the AGM100 requires the patient to simply breath into a mouthpiece and can be completed within two minutes.
  • MediPines Corporation, based inCalifornia, is a market leader in respiratory assessment and monitoring of pulmonary gas exchange.

Electromed, Inc. Schedules its Second Quarter Fiscal 2021 Financial Results Conference Call for February 9, 2021 at 5:00 p.m. ET

Retrieved on: 
Tuesday, January 26, 2021
Health, Medical devices, Other Health, Respiratory therapy, Airway clearance therapy, Pulmonary function testing

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function.

Key Points: 
  • Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function.
  • The Company is headquartered in New Prague, Minnesota and was founded in 1992.
  • Further information about Electromed can be found at www.smartvest.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005959/en/

Electromed, Inc. Schedules its First Quarter Fiscal 2021 Financial Results Conference Call for November 10, 2020 at 5:00 p.m. ET

Retrieved on: 
Tuesday, October 27, 2020
General Health, Medical devices, Seniors, Consumer, Health, Respiratory therapy, Airway clearance therapy, Pulmonary function testing

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function.

Key Points: 
  • Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function.
  • The Company is headquartered in New Prague, Minnesota and was founded in 1992.
  • Further information about Electromed can be found at www.smartvest.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006152/en/

PAOG - New Independent CBD Research Appears To Support PAOG RespRx Research

Retrieved on: 
Tuesday, October 20, 2020
Pulmonology, Respiratory therapy, Health, Clinical medicine, RTT, Respiratory physiology, Chronic obstructive pulmonary disease, Pulmonary fibrosis, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Lung, Pulmonary function testing

RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD derived from a patented cannabis extraction method- U.S. Patent No.

Key Points: 
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD derived from a patented cannabis extraction method- U.S. Patent No.
  • In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate.
  • Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Preclinical Respiration and Inhalation Lab Equipment Market: COVID-19 Business Continuity Plan | Evolving Opportunities with 4DMedical Ltd and CH Technologies USA Inc. | Technavio

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Medical devices, Health, Science, Research, Health, Medical equipment, Plethysmograph, Pulmonary function testing, Respiratory therapy, Sexual health, Respiration, Animal physiology, Respiratory system, Medicine

The global preclinical respiration and inhalation lab equipment market is expected to grow by USD 2.26 million as per Technavio.

Key Points: 
  • The global preclinical respiration and inhalation lab equipment market is expected to grow by USD 2.26 million as per Technavio.
  • In addition, technological advancements and increasing awareness of plethysmographs are factors anticipated to boost the growth of the preclinical respiration and inhalation lab equipment market.
  • All these factors are fueling further activities in respiratory research, which is contributing to the growth of the global preclinical respiration and inhalation lab equipment market.
  • Major Five Preclinical Respiration and Inhalation Lab Equipment Companies:
    4DMedical Ltd operates its business through a unified segment.